Immunotherapy – harnessing the body’s immune system to fight cancer

Immunotherapy is a groundbreaking approach in cancer treatment that empowers the body’s own immune system to recognize and attack tumor cells. Unlike chemotherapy or radiation, which directly target cancer cells, immunotherapy works by modulating immune activity—removing inhibitory signals, enhancing T-cell function, or introducing engineered immune cells. Key mechanisms include checkpoint inhibition, which prevents cancer cells from turning off T cells; adoptive cell therapy, where immune cells are modified to target tumors; and cancer vaccines, which prime the immune system to recognize tumor-specific antigens.

By leveraging the body’s natural defenses, immunotherapy can offer durable responses, precision targeting, and potential long-term control of cancer.

Cancer care has undergone a transformative shift over the past decade. While surgery, chemotherapy, and radiotherapy remain central pillars, immunotherapy has emerged as a revolutionary approach, leveraging the body’s own immune system to recognize and eradicate cancer cells. Unlike traditional treatments that act directly on tumor tissue, immunotherapy amplifies the immune response, creating highly personalized and potentially durable anti-cancer effects. This innovative strategy has opened new possibilities for patients with advanced, metastatic, or treatment-resistant cancers.

Understanding immunotherapy

Immunotherapy is not a single treatment but a class of therapies designed to stimulate, restore, or enhance the immune system’s natural ability to combat malignancy. Tumors often develop sophisticated mechanisms to evade immune detection, such as expressing inhibitory checkpoint proteins or creating immunosuppressive microenvironments. Immunotherapy works by removing these barriers or redirecting immune activity toward tumor cells.

The main categories of immunotherapy include:

1. Checkpoint inhibitors: Drugs that block proteins such as PD-1, PD-L1, or CTLA-4, which cancer cells use to suppress immune attacks. Examples include Nivolumab, Pembrolizumab, and Ipilimumab.
2. Adoptive cell therapy: Harvesting and engineering a patient’s immune cells to target tumor-specific antigens, then reinfusing them. CAR-T therapy is a prominent example.
3. Cancer vaccines: Therapeutic or preventive vaccines that stimulate the immune system to recognize tumor antigens.
4. Cytokine therapy: Using signaling proteins such as interleukins or interferons to boost immune cell activity.
5. Oncolytic viruses: Engineered viruses that selectively infect tumor cells while activating systemic immune responses.

Why immunotherapy is a game-changer

Immunotherapy offers several advantages over traditional cancer treatments:

• Precision and personalization: Targets cancer cells while sparing healthy tissue.
• Durable responses: Long-lasting remission is possible, even in advanced-stage disease.
• Combination therapy potential: Can be paired with chemotherapy, radiotherapy, or targeted therapy to enhance outcomes.
• Tumor-agnostic application: Effective in cancers with high mutational burden (TMB) or microsatellite instability (MSI) across multiple organs.

Real-world examples

Melanoma: Checkpoint inhibitors have dramatically improved survival in metastatic melanoma, with some patients achieving durable remission.

Non-small cell lung cancer (NSCLC): Immunotherapy with drugs like nivolumab or atezolizumab has become standard care, especially in patients with high PD-L1 expression.

MSI-high colorectal cancer: PD-1 inhibitors have shown remarkable efficacy in mismatch repair-deficient tumors, even in refractory cases.

Biomarkers guide therapy

Biomarkers help predict who will respond:

• PD-L1 expression: Higher levels correlate with improved response to PD-1/PD-L1 inhibitors.
• Tumor mutational burden (TMB): More mutations generate neoantigens, enhancing immune recognition.
• Microsatellite instability (MSI): MSI-high tumors are more immunogenic.
• Tumor-infiltrating lymphocytes (TILs): Higher T-cell density predicts better response.

Liquid biopsies allow dynamic monitoring of these biomarkers, enabling early detection of resistance and real-time treatment adaptation.

Challenges and limitations

Immunotherapy is not universally effective. Challenges include:

1. Variable response: Only a subset of patients benefit. Tumor resistance mechanisms include loss of antigen presentation or an immunosuppressive microenvironment.
2. Immune-related toxicities (irAEs): Overactivation can inflame organs such as the lungs, colon, liver, or endocrine glands.
3. Cost and accessibility: Advanced immunotherapies can be expensive and may not be available in all regions.
4. Tumor microenvironment: “Cold” tumors with low immune cell infiltration respond poorly, requiring strategies to convert them into “hot” tumors.

Emerging Strategies

• Dual checkpoint blockade: Combining PD-1 and CTLA-4 inhibitors to enhance T-cell activation.
• Personalized neoantigen vaccines: Customized for each patient’s tumor mutations.
• Adoptive cell therapy in solid tumors: Engineering T cells to infiltrate and attack solid tumors.
• Microbiome modulation: Gut bacteria can influence response to immunotherapy.
• Combination therapies: Using radiotherapy, chemotherapy, or targeted agents to boost immune activity.

Patient perspective

Patients may benefit from:

• Less systemic toxicity than traditional chemotherapy.
• Potential for long-term remission and improved quality of life.
• Tailored therapy based on tumor biology.

Multidisciplinary care is essential, involving oncologists, immunologists, pathologists, and genetic counselors for optimal outcomes.

Clinical and research outlook

The future is promising:

• Expanded indications: Previously “non-immunogenic” tumors may respond with combination strategies.
• Precision Oncology Integration: Combining tumor genomics, TME analysis, and liquid biopsy for personalized treatment.
• Global Access: Clinical trials and policy reforms are improving access worldwide.

Conclusion

Immunotherapy has redefined cancer treatment by shifting the focus from generalized cytotoxic therapy to immune-driven, personalized strategies. With biomarker-guided therapy, advanced monitoring, and combination approaches, clinicians can achieve durable responses and improve patient outcomes. While challenges remain—immune-related toxicity, variable response, and cost—ongoing innovation is steadily expanding the potential of immunotherapy.

Disclaimer: This article is for educational purposes and does not replace professional medical advice. Patients should consult their oncology team before making treatment decisions.

END OF ARTICLE